Dec 10, 2013 at 12:36 | Source: CNBC-TV18
Speaking to CNBC-TV18, S Ramesh, chief financial officer, Lupin says the company is expecting to launch about 100 new drugs in the next three years.
Dec 10, 2013 at 10:44 | Source: Moneycontrol.com
Pharma major Lupin announced today that it has received final approval for its Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg / 300 mg from the United States Food and Drugs Administration (FDA) to market a generic version of ViiV Healthcares (ViiV)Trizivir Tablets, 300 mg (base) / 150 mg / 300mg.
Dec 09, 2013 at 19:25 | Source: PTI
The company, which has inked a memorandum of understanding (MoU) with Austell Laboratories, expects to launch the drug in South Africa by mid-2015.
Dec 09, 2013 at 12:02 | Source: ft.com
Since drugs such as penicillin are so widely used - if not abused - the bacteria they fight are now mutating and becoming resistant.
Dec 05, 2013 at 15:29 | Source: PTI
Commenting on the development, Cipla MD & Global CEO Subhanu Saxena said: "Following our ambition to front end and establish a platform to market our own products, Celeris represented an opportunity for a ready-made platform, especially for our respiratory launches in Europe."
Dec 05, 2013 at 15:28 | Source: PTI
In a statement, the company said one of its manufacturing facilities, Jubilant HollisterStier, LLC (JHS) located at Spokane, Washington state, US has been issued a warning letter by US Food and Drug Administration (USFDA).
Dec 05, 2013 at 12:29 | Source: Moneycontrol.com
Jubilant expects that the on-going manufacturing, distribution and sale of products from this facility will not be impacted as the WL will affect new approvals only.
Dec 05, 2013 at 11:15 | Source: Moneycontrol.com
Jubilant Life Sciences' manufacturing facilities, Jubilant HollisterStier, LLC (JHS) located at Spokane, Washington State, US has been issued a Warning Letter (WL) by US Food and Drug Administration (FDA).
Dec 04, 2013 at 09:27 | Source: Reuters
Stung by rules imposed this year to cut a high trade deficit and a record duty on imports, dealers and individual customers are fanning out across Asia to buy gold and sneak it back into the country.
Nov 27, 2013 at 17:07 | Source: CNBC-TV18
Drug-maker Wockhardt has fallen foul of the US drug regulator once again and this time, the focus is on its Chikalthana plant.